A recent global multi-center trial has demonstrated the effectiveness of a new antibody-drug conjugate in treating CD123-positive BPDCN, a rare form of cancer. The study enrolled 84 adult patients, including 33 newly diagnosed cases and 51 patients with relapsed or refractory BPDCN. Patients received the therapy intravenously in a 21-day cycle, showing promising results in both newly diagnosed and relapsed/refractory cases. This breakthrough treatment offers hope for patients with limited options and is a significant advancement in the field of cancer therapy.
Read more about this — here
